Table 1 |. Baseline characteristics of cohort 1 (ACC) and cohort 2 (non-ACC SGC) patients.
| Cohort 1 (n = 32) | Cohort 2 (n = 32) | Overall (n = 64) | |
|---|---|---|---|
| Age, years (min–max) | 58.0 (31–80) | 64.5 (30–87) | 61.5 (30–87) |
| Sex, n (%) | |||
| Female | 19 (59) | 12 (38) | 31 (48) |
| Male | 13 (41) | 20 (63) | 33 (52) |
| Histology, n (%) | |||
| Adenoid cystic carcinoma | 32 (100) | 0 | 32 (50) |
| Salivary duct carcinoma | 0 | 12 (38) | 12 (19) |
| Acinic cell carcinoma | 0 | 7 (22) | 7 (11) |
| Myoepithelial carcinoma | 0 | 3 (9) | 3 (5) |
| Mucoepidermoid carcinoma | 0 | 2 (6) | 2 (3) |
| Unclassified carcinoma ex pleomorphic adenoma | 0 | 2 (6) | 2 (3) |
| Epithelial-myoepithelial carcinoma | 0 | 1 (3) | 1 (2) |
| Cribriform adenocarcinoma of minor salivary gland | 0 | 1 (3) | 1 (2) |
| Secretory carcinoma | 0 | 1 (3) | 1 (2) |
| SWI/SNF-deficient carcinoma with myoepithelial features | 0 | 1 (3) | 1 (2) |
| AR+ high-grade carcinoma NOS | 0 | 1 (3) | 1 (2) |
| Adenocarcinoma NOS | 0 | 1 (3) | 1 (2) |
| ECOG, n (%) | |||
| 0 | 15 (47) | 21 (66) | 36 (56) |
| 1 | 17 (53) | 11 (34) | 28 (44) |
| Primary origin, n (%) | |||
| Major salivary gland | 10 (31) | 28 (88) | 38 (59) |
| Minor salivary gland | 15 (47) | 4 (13) | 19 (30) |
| Non-salivary gland | 7 (22) | 0 | 7 (11) |
| Brain metastases, n (%) | |||
| No | 31 (97) | 27 (84) | 58 (91) |
| Yes, treated | 1 (3) | 1 (3) | 2 (3) |
| Yes, untreated | 0 | 4 (13) | 4 (6) |
| Previous palliative chemotherapy, n (%) | |||
| No | 22 (69) | 22 (69) | 44 (69) |
| Yes | 10 (31) | 10 (31) | 20 (31) |
| Previous targeted therapya, n (%) | |||
| No | 20 (63) | 24 (75) | 44 (69) |
| Yes | 12 (38) | 8 (25) | 20 (31) |
| Previous anti-AR therapy, n (%) | |||
| No | 32 (100) | 24 (75) | 56 (88) |
| Yes | 0 | 8 (25) | 8 (13) |
| Previous anti-HER2 therapy, n (%) | |||
| No | 32 (100) | 31 (97) | 63 (98) |
| Yes | 0 | 1 (3) | 1 (2) |
| Prior lines of systemic, palliative therapy, n (%) | |||
| 0 | 14 (44) | 15 (47) | 29 (45) |
| 1–2 | 16 (50) | 12 (38) | 28 (44) |
| ≥3 | 2 (6) | 5 (16) | 7 (11) |
Percentages may not add up to 100 due to rounding.
a
Excluding therapies targeting AR or HER2. Primary subsites are listed in Supplementary Table 1.